Ongoing Studies

Ongoing Studies

Biosense Webster, Inc. partners with leading physicians globally to conduct clinical studies to evaluate novel technologies for the treatment of complex heart rhythms and conditions.

Biosense Webster, Inc. partners with leading physicians globally to conduct clinical studies to evaluate novel technologies for the treatment of complex heart rhythms and conditions.

Image of smartfIRE study overview. Registration trial in 10 centers in Europe with patients 17-75 years old.

smartfIRE Study

A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) With the THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator (smartfIRE)

Design and objective: Prospective, multicenter, single-arm study to demonstrate the safety and long-term effectiveness of the BWI IRE ablation system (THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter with TRUPULSE™ Generator in conjunction with the CARTO™ 3 System) when used for isolation of pulmonary veins in treatment of participants with symptomatic drug refractory paroxysmal atrial fibrillation.

The THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter and TRUPULSE™ Generator are currently investigational and are not approved by regulatory bodies in any market.

Image of afIRE study overview. Registrational trial in 6 centers in China with patients 18-75 years old.​

afIRE Study

A Study of Multi-Electrode Circular Irreversible Electroporation (IRE) Catheter and Multi-Channel IRE Generator in Paroxysmal Atrial Fibrillation (afIRE)

Design and objective: Prospective, multicenter, single-arm study to demonstrate the safety and long-term effectiveness of the BWI IRE ablation system (VARIPULSE™ Catheter and TRUPULSE™ Generator in conjunction with the CARTO™ 3 System) when used for isolation of pulmonary veins in treatment of participants with symptomatic drug refractory paroxysmal atrial fibrillation.

The VARIPULSE™ Catheter and TRUPULSE™ Generator are currently investigational and are not approved by regulatory bodies in any market.

Image of admIRE study overview. Registration trial in 30 centers in the United States with patients 18-75 years old.​

admIRE Study

Assessment of Safety and Effectiveness in Treatment Management  of Atrial Fibrillation With the BWI IRE Ablation System (admIRE)

Design and objective: Prospective, multi-center, single-arm study to demonstrate the safety and long-term effectiveness of the BWI IRE ablation system (VARIPULSE™ Catheter and TRUPULSE™ Generator in conjunction with the CARTO™ 3 System) when used for isolation of pulmonary veins in treatment of participants with symptomatic drug refractory paroxysmal atrial fibrillation.

The VARIPULSE™ Catheter and TRUPULSE™ Generator are currently investigational and are not approved by regulatory bodies in any market.

Image of inspIRE study overview. Registration trial in 13 centers in Europe and Canada with patients 18-75 years.​

inspIRE Study

A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE) (inspIRE)

Design and objective: Prospective, multi-center, single-arm study to demonstrate the safety and long-term effectiveness of the IRE system (Circular IRE Catheter and IRE Generator) when used for isolation of the atrial pulmonary veins in treatment of participants with symptomatic, drug refractory paroxysmal atrial fibrillation.

The VARIPULSE™ Catheter and TRUPULSE™ Generator are currently investigational and are not approved by regulatory bodies in any market.

Image of COSMOS study overview. Registration trial with 4 centers in Europe with patients 18 years or older.​

COSMOS Study

A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter (COSMOS)

Design and objective: Prospective, multi-center, single-arm study to demonstrate the safety and performance of the investigational catheter for intracardiac mapping in the atria and ventricles.

The CLARYSENSE™ Catheter is currently investigational and are not approved by regulatory bodies in any market.

Image of SECURE study overview, Post-market studies with 14 centers in EMEA and globally with patients of all ages.​

SECURE Study

An Observational Post-Marketing Study Using Commercially Approved Biosense Webster, Inc. (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias

Design and objective: Prospective, multi-center, observational, post-marketing study to assess acute and long-term safety and performance during routine-use standard cardiac arrhythmia ablation procedures while using commercially approved Biosense Webster, Inc. medical devices.